Search

Search Constraints

You searched for: Author/Creator Chauhan, Dharminder

Search Results

1. A 3D‐Bioprinted Multiple Myeloma Model (Adv. Healthcare Mater. 7/2022). Issue 7 (6th April 2022)

2. A 3D‐Bioprinted Multiple Myeloma Model. Issue 7 (23rd September 2021)

3. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. (20th April 2016)

4. A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results. (26th October 2017)

5. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. (9th May 2016)

6. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study. Issue 5 (May 2020)

7. Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Issue 12 (21st December 2017)